MESOBLAST LIMITED - Charts / Financials

2.97%

$1.80

Market Cap $2.293B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

MEMPHASYS LIMITED

Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.

REFRESH

Day
Open	$1.84		Day High	$1.86		Day Low	$1.77
Daily Volume	4018872

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
3	$1.80	25472		1	$1.81	1500

Directors & Senior Management

Dr. Silviu Itescu	Chief Executive Officer, Executive Director
Mr. William M. Burns	Non-Executive Independent Vice Chairman of the Board
Mr. Andrew Chaponnel	Interim Chief Financial Officer
Dr. Fiona See	Senior Vice President, Head - Translational Research
Mr. Peter Howard	General Counsel, Corporate Executive
Dr. Eric A. Rose	Executive Director, Chief Medical Officer
Mr. Justin Horst	Head - Manufacturing
Mr. Michael Schuster	Pharma Partnering
Ms. Geraldine Storton	Head - Regulatory Affairs and Quality Management
Mr. Paul Hughes	Joint Company Secretary
Mrs. Jane Bell	Non-Executive Independent Chairman of the Board
Dr. Gregory George	Director
Ms. Lyn Cobley	Non-Executive Independent Director
Mr. Philip J. Facchina	Non-Executive Independent Director
Mr. Philip R. Krause	Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.80		Change -0.055(2.97%)		Mkt cap ! $2.293B

Open	High	Low	Value	Volume
$1.84	$1.86	$1.77	$7.241M	4.018M

Buyers (Bids)

No.	Vol.	Price($)
3	25472	$1.80

Sellers (Offers)

Price($)	Vol.	No.
$1.81	1500	1

View Market Depth

No.	Vol.	Price($)
1	485	1.780
4	100773	1.770
2	25500	1.765
3	23000	1.760
7	44464	1.750

Price($)	Vol.	No.
1.805	1500	1
1.810	9500	1
1.820	4000	1
1.835	10000	1
1.840	5000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

MSB (ASX) Chart

MESOBLAST LIMITED - Charts / Financials

Directors & Senior Management

Buyers (Bids)

Sellers (Offers)

Top Stories